Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of
the drugs Pegasys and Copegus when used for hepatitis C genotypes 6, 7, 8, and 9. Patients
are randomly assigned (by chance) to either Treatment Group A (Pegasys and Copegus for 24
weeks) or Treatment Group B (Pegasys and Copegus for 48 weeks).